News

Giant-Carlisle donates $3 million to schools

BY Alaric DeArment

CARLISLE, Pa. — A division of Ahold USA is donating millions of dollars to local schools.

Giant Food Stores and Martin’s Food Markets, also known as Giant-Carlisle, announced Wednesday the donation of $3 million to 2,868 public and private schools through its A+ School Rewards program for the 2012-2013 school year. The program has donated more than $16 million since 2005. The program allows local schools to earn money for technology, scholarships, school programs, field trips, playgrounds and other needs.

Landover, Md.-based Giant Food, another Ahold USA banner, also known as Giant-Landover, said it would donate snack packs for the USO of Metropolitan Washington’s Your USO Meal, or YUM Lunch.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

Personal appearance matters to consumers proactive about their health

BY DSN STAFF

Three-in-five consumers indicate that looking their best is an important part of how they measure overall health, according to an online survey of almost 700 AccentHealth viewers conducted in April. However, this figure grows to 73% among those who are most proactive about wellness.

To see more Patient Views, click here

Patient Views is a new, exclusive consumer insights feature that appears in every edition of DSN magazine, as well as the daily e-newsletter DSN A.M. If you could ask 6,000 patients anything at all, what would it be? Send your questions to [email protected].

 

Source: AccentHealth. To view the demographic breakdown of participants, click here.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

FDA approves Genentech drug for lung cancer with genetic mutation

BY Alaric DeArment

SOUTH SAN FRANCISCO, Calif. — The Food and Drug Administration has approved a drug for a type of lung cancer.

Roche subsidiary Genentech and the U.S. subsidiary of Japan’s Astellas Pharma announced the approval of Tarceva (erlotinib) for advanced non-small cell lung cancer whose tumors have mutations that activate the epidermal growth factor receptor. The FDA also approved a test to detect the mutation.

The drug was already approved for advanced NSCLC that did not exhibit the mutation.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES